CClinicalTrials.gg
Status unknownNCT03731754CCRPWARUpdated Nov 9, 2018

"Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection

An interventional study of Traditional Closure and "Cross" closure in Rectal Cancer and Anal Canal Cancer, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-09.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

How to reduce the complications of perineal wound after abdominoperineal resection (APR) has always been a hot topic in the medical field.To reduce the complications of perineal wound and the primary healing of perineal wound must meet the two principles of "unobstructed drainage" and " reduced tension closure".This concept is similar to the concepts of closure of enterostomy in rectal cancer patients. It was reported that use of cross-stitch closure can significantly reduce complications of closure of enterostomy. So the investigator ever used the "cross" closure to reconstruct the perineal wound of APR, which was really decrease the complications of perineal wound. However, more clinical trails was needed to confirm the conclusion.

Read the detailed description

Perineal wound problems after abdominoperineal resection (APR) for rectal cancer is reported in up to 25%~66% of patients,if the perineum does not heal primarily, the secondary wound healing may prolong hospital stay, may necessitate surgical reintervention, and often requires intensive wound care for several months. Great efforts have been taken to reduce the complications of perineal wound of APR, but the incidence of the perineal wound complications are not effectively decreased.

It was reported that one of the most important factors to determine the primary healing of perineal wound is whether the anterior sacral drainage and perineal stump drainage are sufficient and effective or not, which is similar to the concept of closure of enterostomy.

Previously, it was reported that "cross" closure is an effective method of skin closure for stoma reversal, which allows increased surgical exposure, reduces suture, smooth drainage, aesthetic healing simplifies wound care, and gives a neat cosmetic result.

Therefore, because of the success use of "cross" closure in stoma reversal to reduce the complications of perineal wound, the investigator used the "cross" closure to reconstruct the perineal wound of APR, and it really can decrease the complications of perineal wound. However, more clinical trails are needed to confirm the conclusion.

02

Conditions studied

  • Rectal Cancer
  • Anal Canal Cancer

Browse trials for

Keywords

  • Traditional closure
  • "Cross" closure
  • Rectal cancer
  • Anal canal cancer
  • Abdominoperineal resection
03

In context

Rectal Neoplasms

1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's planned enrollment of 346 is above the median of 65 across 1,298 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 211 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age: 18-75 years old;
  2. ECOG performance status: 0-2;
  3. Histologically confirmed rectal cancer or anal canal cancer;
  4. Completely resected the primary tumor;
  5. No evidence of distant metastasis;
  6. Tolerable general anesthesia;
  7. Total radiation dose of 45-50 Gy needed if the patient needs to receive routine segmental radiotherapy;
  8. Provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Emergency surgery required when the patients combined with acute ileus, perforation and hemorrhage;
  2. Extralevator abdominoperineal resection needed;
  3. American Society of Anesthesiologists (ASA) IV or V;
  4. Combined with other tumors;
  5. Severe mental illness;

(7)Serious cardiovascular disease, uncontrolled infections, or other serious uncontrolled concomitant disease; (8)Expectation of lateral lymph node dissection preoperatively

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
346 participants (estimated)

Study arms

  • Active comparator
    Traditional Closure

    Patients receive primary closure discontinuously for reconstruction of APR perineal wound

    Procedure: Traditional Closure

  • Experimental
    "Cross" Closure

    Patients receive "cross" closure for reconstruction of APR perineal wound

    Procedure: "Cross" closure

Interventions

  • ProcedureTraditional Closure

    Primary closure discontinuously the perineal wound of APR

  • Procedure"Cross" closure

    Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.

06

What researchers measure

Primary outcomes

  1. Complication rate of perineal wound

    the complications of perineal wound are include wound infection, wound effusion, wound liquefaction, wound dehiscence, seroma or hematoma ,delayed wound healing, presacral or perineal abscess, perineal or pelvic floor hernia

    Time frame: Within 30 days after operation

Secondary outcomes

  1. Primary wound healing rate

    the Primary wound healing rate within 30 days after operation

    Time frame: Within 30 days after operation

  2. CTCAE grade for complications of perineal wound

    the CTCAE grade for complications of perineal wound within 30 days after surgery

    Time frame: Within 30 days after surgery

  3. The incidence of each complication of perineal wound

    The incidence of each complication of perineal wound within 30 days after surgery

    Time frame: Within 30 days after surgery

  4. The rate of reoperation

    The rate of reoperation within 30 days after surgery

    Time frame: Within 30 days after surgery

  5. The volumes of presacral drainage

    The volumes of presacral drainage within 3, 5, 7 days after surgery

    Time frame: Within 3, 5, 7 days after surgery

  6. The volumes of presacral residual cavity hydrops

    The volumes of presacral residual cavity hydrops within 3 and 7 days postoperatively

    Time frame: 3 and 7 days postoperatively

  7. The times of dressing change of perineal wound

    The times of dressing change of perineal wound within 3, 5, 7 days after surgery

    Time frame: Within 3, 5, 7 days after surgery

  8. Removal time of presacral drainage tube

    Removal time of presacral drainage tube within 30 days after surgery

    Time frame: Within 30 days after surgery

  9. Scar scores for perineal wound and evaluation of patients' overall satisfaction

    Scar scores for perineal wound and evaluation of patients' overall satisfaction within 30 days after surgery

    Time frame: Within 30 days after surgery

  10. Hospital stay after surgery

    Hospital stay after surgery within 30 days after surgery

    Time frame: Within 30 days after surgery

  11. The operation time

    The operation time

    Time frame: Intraoperatively

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03731754
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Collaborators
First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Jinan University, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Southern Medical University, China, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou First People's Hospital, Affiliated Hospital of Guangdong Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Meizhou People's Hospital, Jieyang People's Hospital
Responsible party
Sponsor
First posted
Nov 6, 2018
Start date
Nov 20, 2018 (estimated)
Primary completion
Nov 20, 2020 (estimated)
Completion
Dec 20, 2020 (estimated)
Last update
Nov 9, 2018

Study contacts

Lei Wang, MD, PhD
Contact
leiwangyinhu@126.com
86-20-38254052
Lei Wang, MD, PhD
principal investigator · Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion